Bone Marrow Diseases  >>  Soliris (eculizumab)  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Soliris (eculizumab) / AstraZeneca
NCT00112983: Eculizumab in Treating Patients With Paroxysmal Nocturnal Hemoglobinuria

Completed
3
US
eculizumab
Jonsson Comprehensive Cancer Center
Leukemia
 
06/05
NCT00130000: Eculizumab to Treat Paroxysmal Nocturnal Hemoglobinuria

Completed
3
87
US
Eculizumab
National Heart, Lung, and Blood Institute (NHLBI)
Paroxysmal Hemoglobinuria, Nocturnal
 
06/07
NCT00122317 / 2005-000043-28: Extension Study of Eculizumab in Patients With Transfusion Dependent Paroxysmal Nocturnal Hemoglobinuria (PNH)

Completed
3
187
US, Canada, Europe, RoW
eculizumab, Soliris
Alexion Pharmaceuticals
Paroxysmal Hemoglobinuria, Nocturnal
09/08
10/08

Download Options